pharmanewsdaily
1509 posts
Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics
Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug…
February 28, 2020
COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial
COSMIC-311 clinical trial : US biotech company Exelixis has enrolled the first 100 patients in a phase 3…
February 26, 2020
Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals
Vertex Pharmaceuticals is set to launch its cystic fibrosis drug KALYDECO (ivacaftor) in New Zealand, which will be…
February 26, 2020
ImmunoPrecise Antibodies launches vaccine development program for COVID-19
ImmunoPrecise Antibodies has launched a coronavirus vaccine development program to address the new coronavirus originating in Wuhan, China…
February 24, 2020
Lilly bags Trulicity FDA approval for reducing CV risk in type 2 diabetes patients
Trulicity FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug…
February 22, 2020
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and…
February 20, 2020
Upsher-Smith Laboratories launches three generic drugs in US
Upsher-Smith Laboratories has launched three new products – Fluvoxamine Maleate Tablets, Clonidine Hydrochloride Extended-Release Tablets, and Haloperidol Tablets,…
February 20, 2020
WuXi vaccine manufacturing facility in Ireland gets $3bn contract
Chinese CDMO WuXi Vaccines has signed a 20-year contract worth around $3bn with an undisclosed vaccine company to…
February 18, 2020
Reneo Pharmaceuticals launches REN001 clinical trial in McArdle disease
Reneo Pharmaceuticals has initiated a phase 1b clinical trial of REN001 in glycogen storage disease type V (GSD…
February 18, 2020
KIK-AS clinical trial : Angelman syndrome drug candidate GTX-102 to be evaluated by GeneTx Biotherapeutics
GeneTx Biotherapeutics is set to start the KIK-AS clinical trial for evaluating GTX-102 for the treatment of Angelman…
February 17, 2020